Thomas C Shea

UNCCH, School of Medicine, Medicine

• Home
• Expert Overview
• Profile
• Publications
• Grants
• Patents
• Similar Experts
• Journals
• Trends
• Institutional Network
• Coauthor Network
• Research Network

Thomas C Shea

• Organizations
  University of North Carolina at Chapel Hill
  
  School of Medicine
  
  Medicine
  
  University of North Carolina at Chapel Hill
  
  School of Medicine
  
  Lineberger Comprehensive Cancer Center – Administration and Program Leaders
  
  

Help us refine your profile

This is a list of publications by this researcher, listed chronologically starting with the most recent first. New publications appear in this list weekly. The source of publications and 'cited by' data for this application is Scopus.

  Select All    |   Export

• 1.

  2013

  W A Wood; A M Deal; B B Reeve; A P Abernethy; E Basch; S A Mitchell; C Shatten; Y Hie Kim; J Whitley; J S Serody; et al.

  Cardiopulmonary fitness in patients undergoing hematopoietic SCT: a pilot study

  Bone Marrow Transplantation. 2013.
  0

• 2.

  2013

  William A. Wood; Allison M. Deal; Amy Abernethy; Ethan Basch; Claudio Battaglini; Yoon Hie Kim; Julia Whitley; Charlotte Shatten; Jon Serody; Thomas Shea; et al.

  Feasibility of Frequent Patient-Reported Outcome Surveillance in Patients Undergoing Hematopoietic Cell Transplantation

  Biology of Blood and Marrow Transplantation. 2013;19(3):450-459.
  0

• 3.

  2013

  Randy D. Gascoyne; Craig Moskowitz; Thomas C. Shea

  Controversies in BMT for Lymphoma

  Biology of Blood and Marrow Transplantation. 2013;19(1 SUPPL.):S26-S32.
  0

• 4.

  2012

  W A Wood; J Whitley; R Goyal; P M Brown; A Sharf; R Irons; K V Rao; A Essenmacher; J S Serody; J M Coghill; et al.

  Effectiveness of etoposide chemomobilization in lymphoma patients undergoing auto-SCT

  Bone Marrow Transplantation. 2012.
  0

• 5.

  2012

  Jessica L. Allen; Matthew S. Fore; Jenna Wooten; Philip A. Roehrs; Nazmim S. Bhuiya; Todd Hoffert; Andrew Sharf; Allison M. Deal; Paul Armistead; James Coghill; et al.

  B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways

  Blood. 2012;120(12):2529-2536.
  1

• 6.

  2012

  Thomas C. Shea

  Second Transplants for NHL: If at First You Don't Succeed...

  Biology of Blood and Marrow Transplantation. 2012;18(8):1148-1149.
  0

• 7.

  2012

  Matthew C. Foster; Chirag Amin; Peter M. Voorhees; Hendrik W. Van Deventer; Kristy L. Richards; Anastasia Ivanova; Jennifer Whitman; Wingkeung Michael Chiu; Nathan D. Barr; Thomas Shea

  A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia

  Leukemia and Lymphoma. 2012;53(7):1331-1337.
  1

• 8.

  2012

  Satish Gopal; William A. Wood; Stephanie J. Lee; Thomas C. Shea; Kikkeri N. Naresh; Peter N. Kazembe; Corey Casper; Peter B. Hesseling; Ronald T. Mitsuyasu

  Meeting the challenge of hematologic malignancies in sub-Saharan Africa

  Blood. 2012;119(22):5078-5087.
  3

• 9.

  2012

  Yuri Fedoriw; T. Danielle Samulski; Allison M. Deal; Cherie H. Dunphy; Andrew Sharf; Thomas C. Shea; Jonathan S. Serody; Stefanie Sarantopoulos

  Bone Marrow B cell Precursor Number after Allogeneic Stem Cell Transplantation and GVHD Development

  Biology of Blood and Marrow Transplantation. 2012;18(6):968-973.
  1

• 10.

  2012

  Philip L. McCarthy; Kouros Owzar; Craig C. Hofmeister; David D. Hurd; Hani Hassoun; Paul G. Richardson; Sergio Giralt; Edward A. Stadtmauer; Daniel J. Weisdorf; Ravi Vij; et al.

  Lenalidomide after stem-cell transplantation for multiple myeloma

  New England Journal of Medicine. 2012;366(19):1770-1781.
  60

• 11.

  2012

  Anne W. Beaven; Thomas C. Shea; Dominic T. Moore; Tatyana Feldman; Anastasia Ivanova; Madlyn Ferraro; Peggy Ford; Judith Smith; Andre Goy

  A phase i study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma

  Leukemia and Lymphoma. 2012;53(2):254-258.
  4

• 12.

  2011

  Gregory A. Masters; Xiaofei Wang; Lydia Hodgson; Thomas Shea; Everett Vokes; Mark Green

  A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531

  Lung Cancer. 2011;74(2):258-263.
  1

• 13.

  2011

  Oliver A. Cornely; Franco Aversa; Perry Cook; Brian Jones; Mauricette Michallet; Thomas Shea; Carlos Vallejo

  Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy

  European Journal of Haematology. 2011;87(4):289-301.
  4

• 14.

  2011

  William Wood; Allison Deal; Julia Whitley; Andrew Sharf; Jonathan Serody; Donald Gabriel; Thomas Shea

  Usefulness of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in predicting outcomes for adolescents and young adults with hematologic malignancies undergoing allogeneic stem cell transplant

  Pediatric Blood and Cancer. 2011;57(3):499-505.
  1

• 15.

  2011

  Thomas Shea; Jeffrey Johnson; Peter Westervelt; Sherif Farag; John McCarty; Asad Bashey; Luis Isola; Lee-Anne Baxter-Lowe; Michael Kelly; Kouros Owzar; et al.

  Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901

  Biology of Blood and Marrow Transplantation. 2011;17(9):1395-1403.
  12

• 16.

  2011

  Asad Bashey; Kouros Owzar; Jeffrey L. Johnson; Peggy S. Edwards; Michael Kelly; Lee-Ann Baxter-Lowe; Steven Devine; Sherif Farag; David Hurd; Edward Ball; et al.

  Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Patients with Hematologic Malignancies Who Relapse following Autologous Transplantation: A Multi-institutional Prospective Study from the Cancer and Leukemia Group B (CALGB trial 100002)

  Biology of Blood and Marrow Transplantation. 2011;17(4):558-565.
  3

• 17.

  2011

  Anne W. Beaven; Dominic T. Moore; Andrew Sharf; Jonathan S. Serody; Thomas C. Shea; Don A. Gabriel

  Infusional mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for multiple myeloma

  Cancer Investigation. 2011;29(3):214-219.
  0

• 18.

  2011

  William A. Wood; Julia Whitley; Dominic Moore; Andrew Sharf; Robert Irons; Kamakshi Rao; Jonathan Serody; Jay Coghill; Donald Gabriel; Thomas Shea

  Chemomobilization with etoposide is highly effective in patients with multiple myeloma and overcomes the effects of age and prior therapy

  Biology of Blood and Marrow Transplantation. 2011;17(1):141-146.
  2

• 19.

  2010

  Jonathan E. Kolitz; Stephen L. George; Guido Marcucci; Ravi Vij; Bayard L. Powell; Steven L. Allen; Daniel J. DeAngelo; Thomas C. Shea; Wendy Stock; Maria R. Baer; et al.

  P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808

  Blood. 2010;116(9):1413-1421.
  25

• 20.

  2010

  William Wood; Seema Garg; Grazyna Adamus; Donald Gabriel; Thomas Shea; Jonathan Serody

  Alloimmune Retinopathy Associated with Antibodies to Transducin-α as a Complication of Chronic Graft-Versus-Host Disease

  Biology of Blood and Marrow Transplantation. 2010;16(1):135-138.
  0

• 21.

  2010

  Hillard M. Lazarus; Mei-Jie Zhang; Jeanette Carreras; Brandon M. Hayes-Lattin; Asli Selmin Ataergin; Jacob D. Bitran; Brian J. Bolwell; César O. Freytes; Robert Peter Gale; Steven C. Goldstein; et al.

  A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B Cell Lymphoma: A Report from the CIBMTR

  Biology of Blood and Marrow Transplantation. 2010;16(1):35-45.
  14

• 22.

  2010

  Margaret L. Gulley; Thomas C. Shea; Yuri Fedoriw

  Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia

  Journal of Molecular Diagnostics. 2010;12(1):3-16.
  7

• 23.

  2009

  Timothy S. Fenske; Parameswaran N. Hari; Jeanette Carreras; Mei-Jie Zhang; Rammurti T. Kamble; Brian J. Bolwell; Mitchell S. Cairo; Richard E. Champlin; Yi-Bin Chen; César O. Freytes; et al.

  Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma

  Biology of Blood and Marrow Transplantation. 2009;15(11):1455-1464.
  16

• 24.

  2009

  Amir H. Khandani; Cherie H. Dunphy; Patcharica Meteesatien; Darin L. Dufault; Marija Ivanovic; Thomas C. Shea

  Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on ¹⁸F-fluorodeoxyglucose positron emission tomography

  Nuclear Medicine Communications. 2009;30(8):594-601.
  12

• 25.

  2009

  Matthew Foster; Don A. Gabriel; Thomas Shea

  Role of hematopoietic stem cell transplant in the management of follicular lymphoma

  Oncologist. 2009;14(7):726-738.
  5

• 26.

  2009

  Claudio L. Battaglini; A.C. Hackney; Rey Garcia; Diane Groff; Elizabeth Evans; Thomas Shea

  The effects of an exercise program in leukemia patients

  Integrative Cancer Therapies. 2009;8(2):130-138.
  14

• 27.

  2009

  Richard M. Stone; Kathleen A. Donohue; Wendy Stock; Vera Hars; Charles A. Linker; Thomas Shea; Daniel J. DeAngelo; Guido Marcucci; Clara D. Bloomfield; Richard A. Larson

  A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804

  Cancer Chemotherapy and Pharmacology. 2009;63(5):859-864.
  9

• 28.

  2009

  Kamakshi V. Rao; Larry W. Buie; Thomas Shea; Don A. Gabriel; Terrance Comeau; Robert Irons; Jonathan Serody; Barbara Eron

  Intravesicular Cidofovir for the Management of BK Virus-Associated Cystitis

  Biology of Blood and Marrow Transplantation. 2009;15(3):391-392.
  6

• 29.

  2009

  Thomas C. Shea; Anne W. Beaven; Dominic Moore; Jonathan Serody; Don Gabriel; Nelson Chao; Jon Gockerman; Reynaldo A. Garcia; David Rizzieri

  Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: Increased toxicity without improvement in progression-free survival

  Leukemia and Lymphoma. 2009;50(5):741-748.
  2

• 30.

  2008

  John Feldmann; William R Carpenter; Carrie Lee; Thomas C Shea; James N Atkins; T Flint Gray

  Cancer clinical trials in North Carolina.

  North Carolina medical journal. 2008;69(4):306-308.
  0

• 31.

  2007

  Anne W. Beaven; Thomas C. Shea

  The effect of palifermin on chemotherapy- and radiation therapy-induced mucositis: A review of the current literature

  Supportive Cancer Therapy. 2007;4(4):188-197.
  12

• 32.

  2007

  Anne W. Beaven; Thomas C. Shea

  Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant

  Drugs of Today. 2007;43(7):461-473.
  7

• 33.

  2007

  Thomas C. Shea; Tarun Kewalramani; Yong Mun; Gerald Jayne; Lyndah K. Dreiling

  Evaluation of single-dose palifermin to reduce oral mucositis in fractionated total-body irradiation and high-dose chemotherapy with autologous peripheral blood progenitor cell transplantation

  Journal of Supportive Oncology. 2007;5(4 SUPPL. 2):60-62.
  0

• 34.

  2007

  Thomas C. Shea; Chirag J. Amin

  Where does rituximab fit in the initial treatment of diffuse large B-cell lymphoma - Induction, maintenance, both, or neither?

  American Journal of Hematology/ Oncology. 2007;6(1):39-42.
  0

• 35.

  2006

  Patrick J. Stiff; Christos Emmanouilides; William I. Bensinger; Teresa Gentile; Bruce Blazar; Thomas C. Shea; John Lu; John Isitt; Alessandra Cesano; Ricardo Spielberger

  Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting

  Journal of Clinical Oncology. 2006;24(33):5186-5193.
  70

• 36.

  2006

  Anne W. Beaven; Thomas C. Shea

  Palifermin: A keratinocyte growth factor that reduces oral mucositis after stem cell transplant for haematological malignancies

  Expert Opinion on Pharmacotherapy. 2006;7(16):2287-2299.
  10

• 37.

  2006

  James Coghill; Terrance Comeau; Thomas Shea; Linda Braddy; Nicholas Bandarenko; Araba Afenyi-Annan; Donald Harvey

  Acute Hemolysis in a Patient with Cytomegalovirus Pneumonitis Treated with Intravenous Immunoglobulin (IVIG)

  Biology of Blood and Marrow Transplantation. 2006;12(7):786-788.
  6

• 38.

  2005

  Don A. Gabriel; Thomas C. Shea; Jonathan S. Serody; Dominic T. Moore; Suzanne L. Kirby; Donald Harvey; Carol Krasnov

  Cytoprotection by amifostine during autologous stem cell transplantation for advanced refractory hematologic malignancies

  Biology of Blood and Marrow Transplantation. 2005;11(12):1022-1030.
  11

• 39.

  2005

  Elizabeth B. Lamont; James E. Herndon II; Jane C. Weeks; I. Craig Henderson; Rogerio Lilenbaum; Richard L. Schilsky; Nicholas A. Christakis; Lee S. Schwartzberg; Stephen George; Stephen Grubbs; et al.

  Criterion validity of medicare chemotherapy claims in cancer and leukemia group B breast and lung cancer trial participants

  Journal of the National Cancer Institute. 2005;97(14):1080-1083.
  34

• 40.

  2005

  Robert Z. Orlowski; Peter M. Voorhees; Reynaldo A. Garcia; Melissa D. Hall; Fred J. Kudrik; Tammy Allred; Anandhi R. Johri; Paul E. Jones; Anastasia Ivanova; Hendrik W. Van Deventer; et al.

  Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

  Blood. 2005;105(8):3058-3065.
  229

• 41.

  2004

  Ricardo Spielberger; Patrick Stiff; William Bensinger; Teresa Gentile; Daniel Weisdorf; Tarun Kewalramani; Thomas Shea; Saul Yanovich; Keith Hansen; Stephen Noga; et al.

  Palifermin for oral mucositis after intensive therapy for hematologic cancers

  New England Journal of Medicine. 2004;351(25):2590-2598.
  428

• 42.

  2004

  Francis J. Giles; Roberto Rodriguez; Daniel Weisdorf; John R. Wingard; Paul J. Martin; Thomas R. Fleming; Stuart L. Goldberg; Elias J. Anaissie; Brian J. Bolwell; Nelson J. Chao; et al.

  A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy

  Leukemia Research. 2004;28(6):559-565.
  32

• 43.

  2004

  Celeste Lindley; Thomas Shea; Jeannine McCune; Stacy Shord; Jodi Decker; Donald Harvey; William P. Petros; Don Garbriel; Jonathan Serody; Suzanne Kirby; et al.

  Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: Assessment of a test dose and first dose strategy

  Anti-Cancer Drugs. 2004;15(5):453-459.
  16

• 44.

  2004

  Thomas C. Shea

  How good are we at managing the toxicity of hematopoietic stem cell transplantation?

  Journal of Supportive Oncology. 2004;2(3):237-241.
  0

• 45.

  2004

  Jonathan E. Kolitz; Stephen L. George; Richard K. Dodge; David D. Hurd; Bayard L. Powell; Steven L. Allen; Enrique Velez-Gardcia; Joseph O. Moore; Thomas C. Shea; Eva Hoke; et al.

  Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: Final induction results of cancer and leukemia group B study 9621

  Journal of Clinical Oncology. 2004;22(21):4290-4301.
  68

• 46.

  2003

  Don A. Gabriel; Thomas Shea; Oludamilola Olajida; Jonathan S. Serody; Terrance Comeau

  The Effect of Oral Mucositis on Morbidity and Mortality in Bone Marrow Transplant

  Seminars in Oncology. 2003;30(6 SUPPL. 18):76-83.
  27

• 47.

  2003

  Koen Van Besien; Fausto R. Loberiza Jr.; Ruta Bajorunaite; James O. Armitage; Asad Bashey; Linda J. Burns; Cesar O. Freytes; John Gibson; Mary M. Horowitz; David J. Inwards; et al.

  Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma

  Blood. 2003;102(10):3521-3529.
  199

• 48.

  2003

  Marla C Brumit; Thomas C Shea; Mark E Brecher

  Transfusion medicine illustrated. G-CSF-associated rash in an allogeneic PBPC donor.

  Transfusion. 2003;43(10):1343.
  1

• 49.

  2003

  Marla C. Brumit; Thomas C. Shea; Mark E. Brecher

  G-CSF-associated rash in an allogeneic PBPC donor

  Transfusion. 2003;43(10):1343.
  0

• 50.

  2003

  Thomas C. Shea; Rebecca Bruner; Joseph M. Wiley; Jonathan S. Serody; Scott Sailer; Don A. Gabriel; Eileen Capel; Dominic T. Moore; Georgette Dent; Stuart Bentley; et al.

  An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for patients with hematologic malignancies

  Biology of Blood and Marrow Transplantation. 2003;9(7):443-452.
  6

• 51.

  2003

  Russell J. Schilder; Mark F. Brady; David Spriggs; Thomas Shea; Denise Mackey

  Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: A gynecologic oncology group study

  Gynecologic Oncology. 2003;88(1):3-8.
  23

• 52.

  2002

  Robert Z. Orlowski; Thomas E. Stinchcombe; Beverly S. Mitchell; Thomas C. Shea; Albert S. Baldwin; Stephanie Stahl; Julian Adams; Dixie-Lee Esseltine; Peter J. Elliott; Christine S. Pien; et al.

  Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

  Journal of Clinical Oncology. 2002;20(22):4420-4427.
  492

• 53.

  2002

  Hendrik W. Van Deventer; Melissa D. Hall; Robert Z. Orlowski; Beverly S. Mitchell; Lee R. Berkowitz; Cathe Hogan; Cherie H. Dunphy; Julie Koehler; Thomas C. Shea

  Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia

  American Journal of Hematology. 2002;71(3):184-190.
  5

• 54.

  2002

  Charles L. Sawyers; Andreas Hochhaus; Eric Feldman; John M. Goldman; Carole B. Miller; Oliver G. Ottmann; Charles A. Schiffer; Moshe Talpaz; Francois Guilhot; Michael W.N. Deininger; et al.

  Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study

  Blood. 2002;99(10):3530-3539.
  799

• 55.

  2001

  Thomas C. Shea; Jonathan Serody; Joseph Wiley; Eileen Capel; Donald Gabriel; Sharon Bigelow; Suzanne Kirby

  Allogeneic bone marrow transplantation using cytokine stimulated bone marrow

  Cancer Research, Therapy and Control. 2001;11(1):27-31.
  0

• 56.

  2001

  Don A. Gabriel; Jonathan S. Serody; Suzanne Kirby; Eileen Capel; Sharon Bigelow; Dominic Moore; Thomas C. Shea

  Efficacy of peripheral blood stem cell or mobilized marrow transplant in the treatment of refractory multiple myeloma

  Blood. 2001;96(11 PART II):354b.
  0

• 57.

  2000

  P.J. Stiff; J. Veum-Stone; H.M. Lazarus; L. Ayash; J.R. Edwards; A. Keating; J.P. Klein; D.J. Oblon; T.C. Shea; S. Thome; et al.

  High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: An autologous blood and marrow transplant registry report

  Annals of Internal Medicine. 2000;133(7):504-515.
  37

• 58.

  2000

  J.S. Serody; M.M. Berrey; K. Albritton; S.M. O'brien; E.P. Capel; S.H. Bigelow; D.J. Weber; D.A. Gabriel; J.M. Wiley; M.J. Schell; et al.

  Utility of obtaining blood cultures in febrile neutropenic patients undergoing bone marrow transplantation

  Bone Marrow Transplantation. 2000;26(5):533-538.
  18

• 59.

  2000

  Jonathan S. Serody; Scotty D. Sparks; Yuhua Lin; Eileen J. Capel; Sharon H. Bigelow; Suzanne L. Kirby; Don A. Gabriel; Joseph M. Wiley; Mark E. Brecher; et al.

  Comparison of Granulocyte Colony-Stimulating Factor (G-CSF)-Mobilized Peripheral Blood Progenitor Cells and G-CSF-Stimulated Bone Marrow as a Source of Stem Cells in HLA-Matched Sibling Transplantation

  Biology of Blood and Marrow Transplantation. 2000;6(4 A):434-440.
  36

• 60.

  2000

  Jiri Mayer; Karel Indrak; Vladimir Koza; Hillard Lazarus; Thomas Shea; Thomas E. Peppard; Joyce A. Heiland; Michael Needle; Charles M. Baum

  Leridistim vs. G-CSF mobilization of peripheral blood stem cells when used with cyclophosphamide and etoposide in patients with lymphoma

  Blood. 2000;96(11 PART I):180a.
  0

• 61.

  2000

  H.M. Lazarus; A.L. Pecora; T.C. Shea; O.N. Koç; J.M. White; D.A. Gabriel; B.W. Cooper; S.L. Gerson; M. Krieger; A.P. Sing

  CD34⁺ selection of hematopoietic blood cell collections and autotransplantation in lymphoma: Overnight storage of cells at 4°C does not affect outcome

  Bone Marrow Transplantation. 2000;25(5):559-566.
  18

• 62.

  1999

  T.C. Shea

  Introduction: current issues in high-dose chemotherapy and stem cell support.

  Bone marrow transplantation. 1999;23 Suppl 2:S1-5.
  0

• 63.

  1999

  Elizabeth J. Shpall; Catherine A. Wheeler; Stewart A. Turner; Saul Yanovich; Randy A. Brown; Andrew L. Pecora; Thomas C. Shea; Kenneth F. Mangan; Stephanie F. Williams; C. Fred LeMaistre; et al.

  A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and Filgrastim in high-risk breast cancer patients

  Blood. 1999;93(8):2491-2501.
  70

• 64.

  1999

  Jonathan S. Serody; Donald N. Cook; Suzanne L. Kirby; Elizabeth Reap; Thomas C. Shea; Jeffrey A. Frelinger

  Murine T lymphocytes incapable of producing macrophage inhibitory protein-1α are impaired in causing graft-versus-host disease across a class I but not class II major histocompatibility complex barrier

  Blood. 1999;93(1):43-50.
  32

• 65.

  1999

  T.C. Shea

  Symposium on Stem cell support of high-dose chemotherapy: Emerging trends for hematopoietic recovery, Keystone, Colorado, 10 January 1998: Introduction: Current issues in high-dose chemotherapy and stem cell support

  Bone Marrow Transplantation. 1999;23(SUPPL. 2):S1-S5.
  9

• 66.

  1998

  R.J. Schilder; T.C. Shea

  Multiple cycles of high-dose chemotherapy for ovarian cancer

  Seminars in Oncology. 1998;25(3):349-355.
  10

• 67.

  1997

  M.A. Socinski; T.C. Shea

  High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer.

  Seminars in oncology. 1997;24(4 Suppl 12):S12-45-S12-4551.
  0

• 68.

  1997

  T.C. Shea

  High-dose carboplatin plus paclitaxel with granulocyte colony-stimulating factor and peripheral blood stem-cell support in non-small-cell lung cancer

  Cancer Chemotherapy and Pharmacology, Supplement. 1997;40:S74-S78.
  7

• 69.

  1997

  S.A. Bentley; M.E. Brecher; E. Powell; J.S. Serody; J.M. Wiley; T.C. Shea

  Long-term engraftment failure after marrow ablation and autologous hematopoietic reconstitution: Differences between peripheral blood stem cell and bone marrow recipients

  Bone Marrow Transplantation. 1997;19(6):557-563.
  19

• 70.

  1997

  T.C. Shea

  Mobilization of peripheral blood progenitor cells with paclitaxel-based chemotherapy

  Seminars in Oncology. 1997;24(1 SUPPL. 2):S2-105-S2-107.
  10

• 71.

  1997

  Jonathan S. Serody; Mark E. Brecher; Georgette Dent; Stuart A. Bentley; Jeffrey A. Frelinger; Thomas C. Shea

  A method for the production of CD4+ chronic myelogenous leukemia- specific allogeneic T lymphocytes

  Cancer Research. 1997;57(8):1547-1553.
  9

• 72.

  1997

  M.A. Socinski; T.C. Shea

  High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer

  Seminars in Oncology. 1997;24(4 SUPPL.12):S1245-S1251.
  5

• 73.

  1997

  J.S. Serody; T.C. Shea

  Prevention of infections in bone marrow transplant recipients

  Infectious Disease Clinics of North America. 1997;11(2):459-477.
  23

• 74.

  1996

  D.C. Mair; M.E. Brecher; E. Hom; H.G. Owen; T.C. Shea

  False-positive hepatitis B surface antigen screening test results patients receiving granulocyte-colony-stimulating factor

  Transfusion. 1996;36(11-12):948-951.
  4

• 75.

  1996

  N. Bandarenko; M.E. Brecher; H. Owen; J. Wiley; T. Shea; J. Serody

  Thrombocytopenia in allogeneic peripheral blood stem cell collections.

  Transfusion. 1996;36(7):668-669.
  4

• 76.

  1996

  Mark E. Brecher; Leigh Sims; John Schmitz; Thomas Shea; Stuart A. Bentley

  North American multicenter study on flow cytometric enumeration of CD34+ hematopoietic stem cells

  Journal of Hematotherapy and Stem Cell Research. 1996;5(3):227-236.
  51

• 77.

  1996

  Thomas J. Smith; Howard Ozer; Langdon L. Miller; Charles A. Schiffer; Rodger J. Winn; James R. Anderson; Paul N. Anderson; James O. Armitage; Stacey Beckhardt; Charles L. Bennett; et al.

  Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines

  Journal of Clinical Oncology. 1996;14(6):1957-1960.
  211

• 78.

  1996

  Nikolaos L. Kelekis; Richard C. Semelka; Hae-Jeong Jeon; Ahmed S. Sallah; Thomas C. Shea; John T. Woosley

  Dark ring sign: Finding in patients with fungal liver lesions and transfusional hemosiderosis undergoing treatment with antifungal antibiotics

  Magnetic Resonance Imaging. 1996;14(6):615-618.
  13

• 79.

  1995

  T. Shea; M. Graham; S. Bernard; A. Steagall; J. Wiley; J. Serody; M. Brecher; S. Bentley; C. Johnston; A. Vaisman; et al.

  A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer

  Seminars in Oncology. 1995;22(5 SUPPL. 12):80-85.
  21

• 80.

  1995

  S.A. Bentley; M.A. Taylor; D.E. Killian; S.B. Schoultz; L. McLannan; C.A. Bishop; T.C. Shea; M.E. Brecher

  Correction of bone marrow nucleated cell counts for the presence of fat particles

  American Journal of Clinical Pathology. 1995;104(1):60-64.
  11

• 81.

  1994

  T.F. Gray III; T.C. Shea

  Current status of peripheral blood progenitor cell transplantation

  Seminars in Oncology. 1994;21(5 SUPPL. 12):93-101.
  9

• 82.

  1994

  T.C. Shea; J.R. Mason; M. Breslin; E. Bissent; M. Mullen; R. Taetle

  Reinfusion and serial measurements of carboplatin-mobilized peripheral- blood progenitor cells in patients receiving multiple cycles of high-dose chemotherapy

  Journal of Clinical Oncology. 1994;12(5):1012-1020.
  18

• 83.

  1993

  T.C. Shea; J.R. Mason; A.M. Storniolo; E. Bissent; M. Breslin; M. Mullen; R. Taetle

  High-dose carboplatin chemotherapy with GM-CSF and peripheral blood progenitor cell support: A model for delivering repeated cycles of dose-intensive therapy

  Cancer Treatment Reviews. 1993;19(SUPPL. C):11-20.
  5

• 84.

  1992

  Thomas C. Shea; Anna Maria Storniolo; James R. Mason; Barbara Newton; Michael Mullen; Raymond Taetle; Mark R. Green

  A dose-escalation study of carboplatin/cyclophosphamide/ etoposide along with autologous bone marrow or peripheral blood stem cell rescue

  Seminars in Oncology. 1992;19(1 SUPPL. 2):139-144.
  6

• 85.

  1992

  T.C. Shea; J.R. Mason; A.M. Storniolo; B. Newton; M. Breslin; M. Mullen; D.M. Ward; L. Miller; M. Christian; R. Taetle

  Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: A novel and effective method for delivering multiple courses of dose-intensive therapy

  Journal of Clinical Oncology. 1992;10(3):464-473.
  65

• 86.

  1992

  J.L. Goodman; D.J. Winston; R.A. Greenfield; P.H. Chandrasekar; B. Fox; H. Kaizer; R.K. Shadduck; T.C. Shea; P. Stiff; et al.

  A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

  New England Journal of Medicine. 1992;326(13):845-851.
  700

• 87.

  1992

  T.C. Shea; J.R. Mason

  Biology and clinical application of peripheral blood stem cells

  Current Topics in Microbiology and Immunology. 1992;177:205-214.
  2

• 88.

  1991

  J.P. Eder; A.D. Elias; L. Ayash; C.A. Wheeler; T.C. Shea; L.E. Schnipper; E. Frei III; K.H. Antman

  A phase I trial of continuous-infusion cyclophosphamide in refractory cancer patients

  Cancer Chemotherapy and Pharmacology. 1991;29(1):61-65.
  3

• 89.

  1990

  A.D. Elias; J.P. Eder; T. Shea; C.B. Begg; E. Frei III; K.H. Antman

  High-dose ifosfamide with mesna uroprotection: A phase I study

  Journal of Clinical Oncology. 1990;8(1):170-178.
  80

• 90.

  1990

  T.C. Shea; G. Claflin; K.E. Comstock; B.J.S. Sanderson; N.A. Burstein; E.J. Keenan; B. Mannervik; W.D. Henner

  Glutathione transferase activity and isoenzyme composition in primary human breast cancers

  Cancer Research. 1990;50(21):6848-6853.
  34

• 91.

  1990

  K. Antman; J.P. Eder; A. Elias; L. Ayash; T.C. Shea; L. Weissman; J. Critchlow; S.M. Schryber; C. Begg; B.A. Teicher; et al.

  High-dose thiotepa alone and in combination regimens with bone marrow support

  Seminars in Oncology. 1990;17(1 SUPPL. 3):33-38.
  19

• 92.

  1989

  Y. Wang; B.A. Teicher; T.C. Shea; S.A. Holden; K.W. Rosbe; A. Al-Achi; W.D. Henner

  Cross-resistance and glutathione-S-transferase-π levels among four human melanoma cell lines selected for alkylating agent resistance

  Cancer Research. 1989;49(22):6185-6192.
  45

• 93.

  1989

  T.C. Shea; M. Flaherty; A. Elias; J.P. Eder; K. Antman; C. Begg; L. Schnipper; E. Frei III; W.D. Henner

  A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support

  Journal of Clinical Oncology. 1989;7(5):651-661.
  89

• 94.

  1988

  A.M. Deffie; T. Alam; C. Seneviratne; S.W. Beenken; J.K. Batra; T.C. Shea; W.D. Henner; G.J. Goldenberg

  Multifactorial resistance to Adriamycin: Relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of Adriamycin-sensitive and -resistant P388 leukemia

  Cancer Research. 1988;48(13):3595-3602.
  58

• 95.

  1988

  J.P. Eder; K. Antman; A. Elias; T.C. Shea; B. Teicher; W.D. Henner; S.M. Schryber; S. Holden; R. Finberg; J. Chritchlow; et al.

  Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors

  Journal of the National Cancer Institute. 1988;80(15):1221-1226.
  27

• 96.

  1988

  T.C. Shea; S.L. Kelley; W.D. Henner

  Identification of an anionic form of glutathione transferase present in many human tumors and human tumor cell lines

  Cancer Research. 1988;48(3):527-533.
  63

• 97.

  1988

  T.C. Shea; K.H. Antman; J.P. Eder; A. Elias; W.P. Peters; S. Schryber; W.D. Henner; D.A. Schoenfeld; L.E. Schnipper; et al.

  Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support

  Archives of Dermatology. 1988;124(6):878-884.
  10

• 98.

  1987

  K. Antman; J.P. Eder; A. Elias; T. Shea; W.P. Peters; J. Andersen; S. Schryber; W.D. Henner; R. Finberg; D. Wilmore

  High-dose combination alkylating agent preparative regimen with autologous bone marrow support: The Dana-Farber Cancer Institute/Beth Israel Hospital experience

  Cancer Treatment Reports. 1987;71(2):119-125.
  17

• 99.

  1987

  W.D. Henner; T.C. Shea; E.A. Furlong; M.D. Flaherty; J.P. Eder; A. Elias; C. Begg; K. Antman

  Pharmacokinetics of continuous-infusion high-dose thiotepa

  Cancer Treatment Reports. 1987;71(11):1043-1047.
  8

• 100.

  1986

  J.P. Eder; K. Antman; W. Peters; W.D. Henner; A. Elias; T. Shea; S. Schryber; J. Andersen; S. Come; L. Schnipper

  High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer

  Journal of Clinical Oncology. 1986;4(11):1592-1597.
  60

• 101.

  1985

  T.C. Shea; R. Spark; B. Kane; R.F. Lange

  Non-Hodgkin's lymphoma limited to the adrenal gland with adrenal insufficiency

  American Journal of Medicine. 1985;78(4):711-714.
  32